Sökning: id:"swepub:oai:DiVA.org:uu-379242" >
Anti-androgen monot...
Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer : a register-based, observational study
-
- Thomsen, Frederik Birkebaek (författare)
- Univ Copenhagen, Rigshosp, Dept Urol, Copenhagen Prostate Canc Ctr, Ole Maaloes Vej 24,Afs 7521, DK-2200 Copenhagen, Denmark
-
- Bosco, Cecilia (författare)
- Kings Coll London, TOUR, Sch Canc & Pharmaceut Sci, London, England
-
- Garmo, Hans (författare)
- Kings Coll London, TOUR, Sch Canc & Pharmaceut Sci, London, England;Uppsala Univ Hosp, Reg Canc Ctr Uppsala Orebro, Uppsala, Sweden
-
visa fler...
-
- Adolfsson, Jan (författare)
- Karolinska Institutet
-
- Hammar, Niklas (författare)
- Karolinska Institutet
-
- Stattin, Pär (författare)
- Uppsala universitet,Urologkirurgi
-
- Van Hemelrijck, Mieke (författare)
- Kings Coll London, TOUR, Sch Canc & Pharmaceut Sci, London, England;Karolinska Inst, Inst Environm Med, Unit Epidemiol, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2019
- 2019
- Engelska.
-
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 58:1, s. 110-118
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background:In randomised controlled trials, men with advanced, non-metastatic prostate cancer (PCa) treated with anti-androgen monotherapy (AA) had similar all-cause mortality as men treated with gonadotropin-releasing hormone (GnRH) agonists. Using real-world evidence (i.e., observational data), we aimed to further assess the difference in mortality between these two drug categories.Material and Methods:We emulated a trial using data from Prostate Cancer data Base Sweden 3.0. We specifically focused on men diagnosed in 2006-2012 with high-risk PCa who had no distant metastasis. They either received primary hormonal therapy with AA (n=2078) or GnRH agonists (n=4878) who were followed for a median time of 5 years. Risk of death from PCa and other causes was assessed using competing risk analyses and Cox proportional hazards regression analyses, including propensity score matching.Results:The cumulative 5-year PCa mortality was lower for men treated with AA (16% [95% confidence interval, CI, 15-18%]) than men treated with GnRH agonists (22% [95% CI 21-24%]). The 5-year other cause mortality was also lower for men on AA (17% [95% CI 15-19%] compared to men on GnRH agonists (27% [95% CI 25-28%]). In regression analyses, the risk of PCa death was similar, GnRH agonists versus AA (reference), hazard ratio (HR) 1.08 (95% CI 0.95-1.23), but the risk of death from all causes was higher for men on GnRH agonists, HR 1.23 (95% CI 1.13-1.34). Consistent results were seen in the propensity score-matched cohort.Conclusion:Our results indicate that the use of AA as primary hormonal therapy in men with high-risk non-metastatic PCa does not increase PCa-specific mortality compared to GnRH. Using AA instead of GnRH agonists may result in shorter time on/exposure to GnRH-treatment, which may reduce the risk of adverse events associated with this treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas